Reliance Institute of Life Sciences

Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

Retrieved on: 
Wednesday, September 6, 2023
AWIS, Alector, Drug development, University, Senior, Pacific Ocean, Drug discovery, Medication, Clinical trial, University of the Pacific Arthur A. Dugoni School of Dentistry, NAM, Genentech, Medicine, Doctor of Philosophy, DSM-IV codes, Reliance Institute of Life Sciences, National academy, National Academy of Medicine, National Center for Advancing Translational Sciences, MD, Medicinal chemistry, UCSF, Patient, Kidney, Cancer, AAAS, Biological engineering, Growth, Association for Women in Science, LOS, Pharmacology, Therapy, IND, Kidney disease, Pharmaceutical industry, Science, Research, Woman

LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the appointment of Sara Kenkare-Mitra, PhD to the Company’s Board of Directors, effective September 6, 2023.

Key Points: 
  • LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the appointment of Sara Kenkare-Mitra, PhD to the Company’s Board of Directors, effective September 6, 2023.
  • “We are thrilled to welcome Dr. Kenkare-Mitra to our Board of Directors and know that her extensive drug development and corporate leadership experience will make an immediate impact here at Unicycive,” said Shalabh Gupta, MD, Chief Executive Officer.
  • “Sara adds a broad skill set to our Board with leadership expertise spanning research, preclinical and clinical development, translational medicine, manufacturing, and regulatory.
  • She has served as a board member of the Genentech foundation and the Association of Women in Science (AWIS).

RCH Solutions, a leading Bio-IT Strategy and Services Company, Introduces Bio-IT Navigator

Retrieved on: 
Thursday, August 17, 2023
Science, Tim Riener, Data management, Organization, R, Bio-1, Biopharma LLC, Environment, RCH, Reliance Institute of Life Sciences, Fine chemical, Management

WAYNE, Pa., Aug. 17, 2023 /PRNewswire-PRWeb/ -- RCH Solutions, a leading Bio-IT services company introduces Bio-IT Navigator, a turnkey program designed to provide comprehensive support and guidance to Biotechs and Pharmas in the Life Sciences. The service offers a complimentary 60-minute consultation and best practices audit, delivering expert advice and insights to address the unique IT challenges faced by R&D departments, particularly in start-up and emerging companies.

Key Points: 
  • Designed to help start-up and emerging biopharmas develop or evolve their compute strategy, Bio-IT Navigator offers a one-hour, complimentary assessment and strategy consultation.
  • WAYNE, Pa., Aug. 17, 2023 /PRNewswire-PRWeb/ -- RCH Solutions , a leading Bio-IT services company introduces Bio-IT Navigator , a turnkey program designed to provide comprehensive support and guidance to Biotechs and Pharmas in the Life Sciences.
  • "Bio-IT Navigator helps emerging companies with still limited team resources point the compass as they consider or look to evolve their compute environment strategy," said Michael Riener, CEO of RCH Solutions.
  • "With the introduction of Bio-IT Navigator, we're lowering the barrier to access this level of highly specialized guidance to help companies still in their earliest stage position themselves for long-term success."

Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer

Retrieved on: 
Tuesday, August 1, 2023
DNA, GSK plc, Drug development, Cyclin, Female, Therapy, University, DDR, ARM, Cancer, Medication, Postgraduate education, Weill Cornell Medical Center, AstraZeneca, Marketing, Reliance Institute of Life Sciences, Boehringer Ingelheim, Regenerative medicine, Wharton School of the University of Pennsylvania, Graduate, Patient, SAN, State University of New York Upstate Medical University, Cell, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Commodity, Research, FDA, Woman, Cornell University, Widener University Commonwealth Law School, Pharmaceutical industry, Medical imaging, Science, Biology

NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Kimberly Freeman as Chief Strategy Officer.

Key Points: 
  • NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Kimberly Freeman as Chief Strategy Officer.
  • In this role, she will support and implement Zentalis’ long-term portfolio strategy.
  • Ms. Freeman joins Zentalis with over 25 years of clinical development and strategic leadership experience, including deep expertise in oncology, particularly in gynecologic malignancies and the DNA damage response (DDR) pathway.
  • “Kimberly brings an outstanding track record of building and executing drug development and franchise strategies that will be invaluable to Zentalis as we seek to capitalize on the significant opportunity we see with azenosertib across a broad array of tumor types,” said Dr. Kimberly Blackwell, Chief Executive Officer of Zentalis.

FTI Consulting Adds Two Senior Life Sciences Professionals to Health Solutions Practice

Retrieved on: 
Monday, April 24, 2023
FCN, Therapy, Senior, FTI Consulting, Strategic planning, Quality, Reliance Institute of Life Sciences, Medco Health Solutions, NYSE, FTI, Nursing

WASHINGTON, April 24, 2023 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Anthony Gotzis as a Senior Managing Director and Jacinthe Guindon as a Managing Director in the Life Sciences offering within the firm’s Health Solutions practice.

Key Points: 
  • WASHINGTON, April 24, 2023 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Anthony Gotzis as a Senior Managing Director and Jacinthe Guindon as a Managing Director in the Life Sciences offering within the firm’s Health Solutions practice.
  • “Our clients in the life sciences industry look to us to solve their biggest business challenges,” said Charles Overstreet , Global Leader of the Health Solutions practice at FTI Consulting.
  • In his role at FTI Consulting, Mr. Gotzis will lead the Life Sciences R&D and Quality capability team within the Life Sciences offering.
  • In her role at FTI Consulting, she will focus on clinical development, clinical compliance and trial and portfolio management.

AmplifyBio Chooses Blue Mountain to Achieve GMP Compliance and Advance Digital Strategy

Retrieved on: 
Thursday, December 1, 2022
Toxicology, Quality, Title 21 CFR Part 11, Good manufacturing practice, CCMS, Calibration, GxP, Patient, Medical device, CFR, Maintenance, Gene therapy, Disease, GMP, Reliance Institute of Life Sciences, Software as a service, EAM, Cell, Mobile enterprise asset management, Computerized maintenance management system, CMMS, Safety, RAM, Fine chemical, Gemstone, Risk management, Biotechnology, Medication

STATE COLLEGE, Pa., Dec. 1, 2022 /PRNewswire/ -- AmplifyBio has selected Blue Mountain Regulatory Asset Manager (RAM) to help with incorporating industry best practices and ensuring electronic records compliance.

Key Points: 
  • STATE COLLEGE, Pa., Dec. 1, 2022 /PRNewswire/ -- AmplifyBio has selected Blue Mountain Regulatory Asset Manager (RAM) to help with incorporating industry best practices and ensuring electronic records compliance.
  • In one seamlessly integrated system, Blue Mountain RAM provides world-class calibration and maintenance management, all while ensuring GxP compliance.
  • To learn more about AmplifyBio, visit https://www.amplify-bio.com/
    About Blue Mountain Quality Resources:
    Leading the Life Sciences in GMP asset management for 30+ years, Blue Mountain offers deep Life Sciences domain expertise.
  • To learn more about Blue Mountain, visit: https://coolblue.com
    For more information, contact Akashi Perera at 814-234-2417 or [email protected].

AmplifyBio Chooses Blue Mountain to Achieve GMP Compliance and Advance Digital Strategy

Retrieved on: 
Thursday, December 1, 2022
Toxicology, Quality, Title 21 CFR Part 11, Blue Mountain, CCMS, Organization, Calibration, Partnership, GxP, Medical device, CFR, Maintenance, Gene therapy, GLP, Disease, Drug development, GMP, Reliance Institute of Life Sciences, Software as a service, EAM, Health, Therapy, Cell, Mobile enterprise asset management, Computerized maintenance management system, CMMS, Safety, RAM, Fine chemical, Biotechnology, Medication

"We are honored to be selected as a partner to elevate Amplify Bio's GMP program by providing a clear path towards digital maturity," said the CEO of Blue Mountain, David Rode.

Key Points: 
  • "We are honored to be selected as a partner to elevate Amplify Bio's GMP program by providing a clear path towards digital maturity," said the CEO of Blue Mountain, David Rode.
  • In one seamlessly integrated system, Blue Mountain RAM provides world-class calibration and maintenance management, all while ensuring GxP compliance.
  • AmplifyBio's is proud to partner with Blue Mountain and be able to provide the regulatory compliance and quality assurance drug development clients require to advance medical breakthroughs, treatments, and cures for disease.
  • Connect with AmplifyBio on LinkedIn: https://www.linkedin.com/company/71550758
    Leading the Life Sciences in GMP asset management for 30+ years, Blue Mountain offers deep Life Sciences domain expertise & SaaS solutions to help companies transform their manufacturing processes and achieve the highest level of GMP digital maturity.

Cloud Automation is Speeding Up Innovation in Pharma and Life Sciences

Retrieved on: 
Monday, October 10, 2022
Pressure, Morpheus, API, Marketing, AstraZeneca, Risk, Efficiency, Reliance Institute of Life Sciences, Policy, Organization, Research, VMS, Technology, Container, Cloud computing, Frustration, Safety, List, FDA, Fine chemical, Pharmaceutical industry, Cluster

GREENWOOD VILLAGE, Colo., Oct. 10, 2022 /PRNewswire-PRWeb/ -- In recent years, the life sciences and pharma industries have experienced an increase in regulatory oversight while also facing pressure to respond to global healthcare crises. This tension between regulation and innovation will only increase as security and data privacy concerns limit the ability of many industries to take advantage of public cloud services.

Key Points: 
  • The Morpheus hybrid cloud management platform speeds up innovation while decreasing risk, in highly regulated industries, such as life sciences and pharma.
  • "By optimizing data sharing and advancing collaboration and innovation, cloud computing can facilitate world-changing discoveries."
  • Herein lies a unique difficulty for those operating within life sciences and pharma industries organizations must innovate at the fastest pace possible to compete while still adhering to critical regulatory requirements.
  • In the future, pharma and life sciences organizations that are highly automated will be poised to be able to innovate the fastest.

Epic Launches Life Sciences Program, Unifying Clinical Research with Care Delivery

Retrieved on: 
Wednesday, September 14, 2022
Cosmos, Clinical trial, Research, List of life sciences, Organization, Friction, News, Epic, Patient, CRO, Multimedia, Efficiency, Edwards Lifesciences, View, Program, Reliance Institute of Life Sciences, Pharmaceutical industry, Online shopping

VERONA, Wis., Sept. 14, 2022 /PRNewswire/ -- Epic announces the release of its Life Sciences program, expanding its work to bring together the disconnected parts of healthcare. The program is built to help providers, pharmaceutical companies, and medical device manufacturers recruit research participants, expand clinical trial access to underrepresented communities, and speed up the development of new therapies.

Key Points: 
  • "The Life Sciences program is designed to create a seamless connection between participant patients, healthcare providers, and research sponsors through the use of a single system," said Alan Hutchison, vice president at Epic.
  • "Unifying clinical research with care delivery and building a direct connection to study sponsors will help accelerate the development of new therapies by making studies more efficient, more accessible, and more effective."
  • "The first stage of the Life Sciences program, clinical trial matchmaking, is available today and provider organizations in the Epic community are already signing up," said Seth Howard, vice president of research and development at Epic.
  • Provider organizations in the Epic community and life sciences groups that are interested in study feasibility and clinical trial matchmaking can reach out to [email protected] to learn more.

ACTO launches LAICA™, the first AI-powered conversational assistant for Life Sciences learning

Retrieved on: 
Wednesday, June 15, 2022
MSL, Industry, List of life sciences, Learning, Software as a service, Intelligence, Technology, Human, Artificial intelligence, CEO, LAICA, MRL, MLR, Reliance Institute of Life Sciences, Commercial, Library and information science, Siri, Ecosystem, Voice recognition, ACTO, Partnership, Conference, GLOBE, AI, Pharmaceutical industry, Tutoring, Apple

TORONTO, June 15, 2022 (GLOBE NEWSWIRE) -- ACTO, the only complete commercial learning platform for the Life Science industry, announced the launch of "LAICA" , an artificial intelligence (AI)-powered conversational assistant, like a SIRI, for Life Sciences learning.

Key Points: 
  • TORONTO, June 15, 2022 (GLOBE NEWSWIRE) -- ACTO, the only complete commercial learning platform for the Life Science industry, announced the launch of "LAICA" , an artificial intelligence (AI)-powered conversational assistant, like a SIRI, for Life Sciences learning.
  • LAICA is the only voice search assistant on the market that supports learning for Life Sciences commercial and medical affairs teams in real-time.
  • ACTO and Axioms award-winning partnership provides the Life Sciences industry with an integrated learning ecosystem that combines technology with unforgettable content and scientific expertise that shapes minds and drives results.
  • Building an ecosystem for life sciences, ACTO maintains a network of partnerships with content agencies, data providers, technology companies, and more.

RCH Solutions Launches Career Acceleration Program for Junior IT Engineers

Retrieved on: 
Wednesday, March 30, 2022
Cloud, Cloud computing, RCH, Automation, Growth, Cloud computing architecture, Health care, Research, Certification, Program, Environment, Training and development, Specialization, Solution, CLC bio, Knowledge, DevOps, List of life sciences, Reliance Institute of Life Sciences, Maintenance, Education, Mentorship, Capstone, Medicine, Management, Video game console, Architecture

WAYNE, Pa., March 30, 2022 /PRNewswire-PRWeb/ -- RCH Solutions, a global provider of Bio-IT computing expertise for Life Sciences and Healthcare firms of all sizes, is proud to announce a new two-year Career Acceleration Program, RCH CAPstone, for junior and associate-level IT professionals. Participants in the initiative will receive training, mentorship, and incentives designed to create and retain smart, driven leaders in the highly nuanced field of scientific computing in the Life Sciences.

Key Points: 
  • WAYNE, Pa., March 30, 2022 /PRNewswire-PRWeb/ -- RCH Solutions , a global provider of Bio-IT computing expertise for Life Sciences and Healthcare firms of all sizes, is proud to announce a new two-year Career Acceleration Program, RCH CAPstone, for junior and associate-level IT professionals.
  • "Our customers' needs are extremely specialized," said David Orvosh, Director of Managed Services at RCH Solutions.
  • The first iteration of the RCH CAPstone program will include three educational tracks: Cloud Computing, Systems and Workflow Engineering, and DevOps.
  • RCH Solutions (RCH) is a global provider of Bio-IT expertise, helping Life Sciences and Healthcare companies of all sizes clear the path to discovery.